Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 348–349 (2005)Cite this article

boxed-text Lemann M et al. (2005) A randomized double-blind controlled withdrawal trial in Crohn's disease patients in long term remission on azathioprine. Gastroenterology [10.1053/j.gastro.2005.03.031]

Indefinite use of AZA/6-MP in Crohn's disease patients is preferable once remission has been achieved, but monitoring of patients is mandatory as the long-term risk of lymphoma cannot be excluded

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kim PS et al. (1999) Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenetrol 94: 3254–3257

    Article  CAS  Google Scholar 

  2. Fraser AG et al. (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485–489

    Article  CAS  Google Scholar 

  3. Bouhnik Y et al. (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347: 215–219

    Article  CAS  Google Scholar 

  4. Lewis JD et al. (2000) Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118: 1018–1024

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Victoria Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Registrar and Chair of Gastroenterology,

    Sandro Ardizzone & Gabriele Bianchi Porro

  2. Professor and Chief of Institute at L. Sacco University Hospital, Milan, Italy

    Sandro Ardizzone & Gabriele Bianchi Porro

Authors
  1. Sandro Ardizzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriele Bianchi Porro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandro Ardizzone.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Glossary

CROHN'S DISEASE ACTIVITY INDEX

An index composed of subjective and objective parameters: a CDAI score ≤150 indicates clinical remission; >150 indicates active disease; and >450 indicates extremely severe disease

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ardizzone, S., Porro, G. Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission?. Nat Rev Gastroenterol Hepatol 2, 348–349 (2005). https://doi.org/10.1038/ncpgasthep0221

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0221

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing